Exane Derivatives’s Sanofi SNY Stock Holding History

Exane Derivatives’s Portfolio SNY Stock Details SNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-7,700	Closed	-$337K	–	740
2020 Q1	$337K	Buy	+7,700	New	+$368K	0.09%	148
2018 Q4	–	Sell	-1,000	Closed	-$44.5K	–	734
2018 Q3	$44.5K	Buy	+1,000	New	+$42.7K	0.01%	377
2017 Q3	–	Sell	-14,473	Closed	-$693K	–	636
2017 Q2	$693K	Buy	14,473 +12,104	+511%	+$578K	0.15%	107
2017 Q1	$107K	Buy	2,369 +1,598	+207%	+$67.8K	0.02%	224
2016 Q4	$31.2K	Buy	+771	New	+$30.4K	0.01%	333
2016 Q1	–	Sell	-13,721	Closed	-$585K	–	611
2015 Q4	$585K	Buy	13,721 +7,867	+134%	+$362K	0.08%	106
2015 Q3	$278K	Buy	+5,854	New	+$298K	0.04%	162

Other funds holding SNY

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $34.3B AUM 22.63% 1-Year Est. Return

Lazard Asset Management New York $66.1B AUM 33.53% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

Exane Derivatives's SNY Position: Q2 2020 in Review

Exane Derivatives sold out of Sanofi (SNY) in Q2 2020, closing a stake of 7,700 shares — an estimated $337K sold.

Exane Derivatives first reported a position in SNY in Q3 2015 and held it in 7 quarters. The position peaked at $693K in Q2 2017. 583 funds tracked by Wall St. Rank hold SNY as of Q2 2020.

Exane Derivatives reported no remaining Sanofi position as of Q2 2020 after selling out during the quarter.
Exane Derivatives sold 7,700 Sanofi shares in Q2 2020, an estimated $337K.
Exane Derivatives first reported a position in Sanofi in Q3 2015 and held it in 7 quarters.
Exane Derivatives's Sanofi position peaked at $693K in Q2 2017.
583 funds tracked by Wall St. Rank held Sanofi as of Q2 2020.

Based on Exane Derivatives's 13F filing for Q2 2020, filed 10 Jul 2020.